Navigation Links
Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
Date:5/30/2008

NEW HAVEN, Conn., May 30 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from two clinical trials of its lead anticancer agent Cloretazine(R) (VNP40101M) in acute myelogenous leukemia (AML) would be presented in posters at the 2008 American Society of Clinical Oncology (ASCO(R)) Annual Meeting in Chicago, Illinois.

The poster (Abstract #7051) entitled "A double blind placebo-controlled randomized phase III study of high-dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients with first relapse of AML" will be presented at McCormick Place, South Hall A1, Board 38E from 8:00 a.m. to 12:00 p.m. on Saturday, May 31, 2008. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on May 31, 2008 at 7:00 a.m. Eastern Time.

The poster (Abstract #7025) entitled "A phase II study of VNP40101M in elderly patients with de novo poor risk AML" will be presented at McCormick Place, Room E450a, Board 15 from 2:00 p.m. to 6:00 p.m. on Monday June 2, 2008. A poster discussion will take place at 5:30 p.m. in Room E354a. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on June 2, 2008 at 1:00 p.m. Eastern Time.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a si
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul ... at Georgetown,University Medical Center, and principal investigator ... American Phase III clinical trial,for tramiprosate (ALZHEMED(TM)) ... product candidate for the treatment of,Alzheimer's disease ...
... 12, 2007 - Proprietary Pulsed,Electromagnetic Field ... (AMEX:II), improved neuron survival in a,standard ... researchers,reported today in a platform presentation ... in Kanazawa,Japan. Inflammation is associated with ...
Cached Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Ivivi's PEMF Technology Significantly Improves Neuron Survival in,Parkinson's Disease Model, Study Finds 2Ivivi's PEMF Technology Significantly Improves Neuron Survival in,Parkinson's Disease Model, Study Finds 3
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... find a colored ribbon representing a disease. A pink ribbon ... ribbon does one think of with lung cancer?, Although white ... from the disease, black may be the only one they ... cancer patients, primarily smokers between the ages of 51 to ... often felt by these patients, the emotional toll it can ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... signalling molecule to the brain reverses Alzheimer-like damage in ... group of brain cells called the basal forebrain cholinergic ... these neurons produce, is lost and, since it is ... ,In London and California, researchers now reveal ...
... wrong sometimes.There has been a rise in the number ... rhythm. ,Many depend on either a pacemaker or ... However sophisticated and accurate devices they may be, sometimes ... Brigham and Women's Hospital in the US have surveyed ...
... derived from the plants Camellia sinensis contains polyphenols in ... which gives the tea its antioxidant properties.,Polyphenols protect the ... , Oxidation produces ... in the body and an increased amount of them ...
... lab mice with full blown versions of of Type 1 Diabetes ... , , In addition Denise ... mice of the immune cells that attack the pancreas and the ... Once the mutinous cells were eliminated,the researchers coaxed the ...
... an autoimmune disease that most often affects women in their ... to attack the joints, which can cause pain, inflammation and ... standard drug used to treat the condition, but one third ... , , Patients taking Methotrexate are prone ...
... part of a medical check. Generally, it is assumed that ... high, and low density lipoprotein (LDL, or 'bad' cholesterol) low. ... At Johns Hopkins University in the US, researchers believe ... is the difference between total cholesterol and HDL. It is ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: